TWST Quote, Financials, Valuation and Earnings

Microbot Medical has a net margin of -40.91% compared to Twist Bioscience's net margin of --. Twist Bioscience's return on equity of -38.12% beat Microbot Medical's return on equity of --.

Twist Bioscience has a consensus price target of $51.81, signalling upside risk potential of 5.95%. On the other hand Microbot Medical has an analysts' consensus of -- which suggests that it could grow by 602.11%. Given that Microbot Medical has higher upside potential than Twist Bioscience, analysts believe Microbot Medical is more attractive than Twist Bioscience.

Twist Bioscience has a beta of 1.822, which suggesting that the stock is 82.223% more volatile than S&P 500. In comparison Microbot Medical has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.938%.

Twist Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbot Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience pays -- of its earnings as a dividend. Microbot Medical pays out -- of its earnings as a dividend.

Twist Bioscience quarterly revenues are $84.7M, which are larger than Microbot Medical quarterly revenues of --. Twist Bioscience's net income of -$34.7M is lower than Microbot Medical's net income of -$3.2M. Notably, Twist Bioscience's price-to-earnings ratio is -- while Microbot Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience is 9.06x versus -- for Microbot Medical. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -40.91% compared to Twist Bioscience's net margin of -18.58%. Twist Bioscience's return on equity of -38.12% beat Retractable Technologies's return on equity of -16.83%.

Twist Bioscience has a consensus price target of $51.81, signalling upside risk potential of 5.95%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Twist Bioscience has higher upside potential than Retractable Technologies, analysts believe Twist Bioscience is more attractive than Retractable Technologies.

Twist Bioscience has a beta of 1.822, which suggesting that the stock is 82.223% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

Twist Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Twist Bioscience quarterly revenues are $84.7M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Twist Bioscience's net income of -$34.7M is lower than Retractable Technologies's net income of -$1.9M. Notably, Twist Bioscience's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience is 9.06x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -40.91% compared to Twist Bioscience's net margin of -4291.67%. Twist Bioscience's return on equity of -38.12% beat Catheter Precision's return on equity of -65.84%.

Twist Bioscience has a consensus price target of $51.81, signalling upside risk potential of 5.95%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Catheter Precision has higher upside potential than Twist Bioscience, analysts believe Catheter Precision is more attractive than Twist Bioscience.

Twist Bioscience has a beta of 1.822, which suggesting that the stock is 82.223% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Twist Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Twist Bioscience quarterly revenues are $84.7M, which are larger than Catheter Precision quarterly revenues of $96K. Twist Bioscience's net income of -$34.7M is lower than Catheter Precision's net income of -$4.1M. Notably, Twist Bioscience's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience is 9.06x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -40.91% compared to Twist Bioscience's net margin of -17.98%. Twist Bioscience's return on equity of -38.12% beat Xtant Medical Holdings's return on equity of -35.98%.

Twist Bioscience has a consensus price target of $51.81, signalling upside risk potential of 5.95%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than Twist Bioscience, analysts believe Xtant Medical Holdings is more attractive than Twist Bioscience.

Twist Bioscience has a beta of 1.822, which suggesting that the stock is 82.223% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Twist Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Twist Bioscience quarterly revenues are $84.7M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Twist Bioscience's net income of -$34.7M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Twist Bioscience's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience is 9.06x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.